111 related articles for article (PubMed ID: 37778291)
1. Exosomes modified with anti-MEK1 siRNA lead to an effective silencing of triple negative breast cancer cells.
Ferreira D; Santos-Pereira C; Costa M; Afonso J; Yang S; Hensel J; McAndrews KM; Longatto-Filho A; Fernandes R; Melo JB; Baltazar F; Moreira JN; Kalluri R; Rodrigues LR
Biomater Adv; 2023 Nov; 154():213643. PubMed ID: 37778291
[TBL] [Abstract][Full Text] [Related]
2. [Silencing RAB27a inhibits proliferation, invasion and adhesion of triple-negative breast cancer cells].
Wang L; Yan Z; Xia Y
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Apr; 43(4):560-567. PubMed ID: 37202191
[TBL] [Abstract][Full Text] [Related]
3. Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy.
Vaidya AM; Sun Z; Ayat N; Schilb A; Liu X; Jiang H; Sun D; Scheidt J; Qian V; He S; Gilmore H; Schiemann WP; Lu ZR
Bioconjug Chem; 2019 Mar; 30(3):907-919. PubMed ID: 30739442
[TBL] [Abstract][Full Text] [Related]
4. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
[TBL] [Abstract][Full Text] [Related]
6. Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer.
Zhao Z; Li Y; Shukla R; Liu H; Jain A; Barve A; Cheng K
Theranostics; 2019; 9(15):4508-4524. PubMed ID: 31285776
[TBL] [Abstract][Full Text] [Related]
7. FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells.
Taliaferro-Smith L; Oberlick E; Liu T; McGlothen T; Alcaide T; Tobin R; Donnelly S; Commander R; Kline E; Nagaraju GP; Havel L; Marcus A; Nahta R; O'Regan R
Oncotarget; 2015 Mar; 6(7):4757-72. PubMed ID: 25749031
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the influence of Human Umbilical Cord Mesenchymal Stem Cells-derived exosomes loaded with miR-3182 on metastatic performance of Triple Negative Breast Cancer cells.
Khazaei-Poul Y; Shojaei S; Koochaki A; Ghanbarian H; Mohammadi-Yeganeh S
Life Sci; 2021 Dec; 286():120015. PubMed ID: 34614416
[TBL] [Abstract][Full Text] [Related]
9. PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling.
Qin H; Liu X; Li F; Miao L; Li T; Xu B; An X; Muth A; Thompson PR; Coonrod SA; Zhang X
Cancer Lett; 2017 Nov; 409():30-41. PubMed ID: 28844713
[TBL] [Abstract][Full Text] [Related]
10. Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT.
Zhu Y; Tao Z; Chen Y; Lin S; Zhu M; Ji W; Liu X; Li T; Hu X
Breast Cancer Res Treat; 2022 May; 193(1):65-81. PubMed ID: 35254603
[TBL] [Abstract][Full Text] [Related]
11. Critical Review on the Different Roles of Exosomes in TNBC and Exosomal-Mediated Delivery of microRNA/siRNA/lncRNA and Drug Targeting Signalling Pathways in Triple-Negative Breast Cancer.
Banerjee M; Rajeswari VD
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838790
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
[TBL] [Abstract][Full Text] [Related]
14. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
15. Exosomes deliver lncRNA DARS-AS1 siRNA to inhibit chronic unpredictable mild stress-induced TNBC metastasis.
Liu X; Zhang G; Yu T; He J; Liu J; Chai X; Zhao G; Yin D; Zhang C
Cancer Lett; 2022 Sep; 543():215781. PubMed ID: 35688263
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in triple negative breast cancer cells.
Zhang C; Yuan W; Wu Y; Wan X; Gong Y
Life Sci; 2021 Feb; 266():118886. PubMed ID: 33310044
[TBL] [Abstract][Full Text] [Related]
17. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
[TBL] [Abstract][Full Text] [Related]
18. Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1.
Cınar V; Hamurcu Z; Guler A; Nurdinov N; Ozpolat B
Breast Cancer; 2022 Nov; 29(6):1106-1120. PubMed ID: 36006564
[TBL] [Abstract][Full Text] [Related]
19. Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer.
Li T; Tao Z; Zhu Y; Liu X; Wang L; Du Y; Cao J; Wang B; Zhang J; Hu X
Cell Death Dis; 2021 Jul; 12(7):684. PubMed ID: 34238922
[TBL] [Abstract][Full Text] [Related]
20. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis.
Yang HL; Thiyagarajan V; Shen PC; Mathew DC; Lin KY; Liao JW; Hseu YC
J Exp Clin Cancer Res; 2019 May; 38(1):186. PubMed ID: 31068208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]